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ABSTRACT: Re-engineered riboswitches that no longer respond to cellular
metabolites, but that instead can be controlled by synthetic molecules, are
potentially useful gene regulatory tools for use in synthetic biology and
biotechnology ﬁelds. Previously, extensive genetic selection and screening
approaches were employed to re-engineer a natural adenine riboswitch to create
orthogonal ON-switches, enabling translational control of target gene
expression in response to synthetic ligands. Here, we describe how a rational
targeted approach was used to re-engineer the PreQ1 riboswitch from Bacillus
subtilis into an orthogonal OFF-switch. In this case, the evaluation of just six
synthetic compounds with seven riboswitch mutants led to the identiﬁcation of
an orthogonal riboswitch−ligand pairing that eﬀectively repressed the
transcription of selected genes in B. subtilis. The streamlining of the re-
engineering approach, and its extension to a second class of riboswitches,
provides a methodological platform for the creation of new orthogonal
regulatory components for biotechnological applications including gene functional analysis and antimicrobial target validation
and screening.
■ INTRODUCTION
Riboswitches are noncoding regions of mRNA that regulate gene
expression through the selective binding of metabolites.1,2 Most
riboswitches are found within the 5′-untranslated regions (5′-
UTRs) of bacterial mRNAs that encode gene products required
for the biosynthesis, catabolism, or transport of the cognate
metabolite.1,2 Riboswitches exhibit a modular architecture
consisting of an aptamer domain that, upon ligand binding,
induces a conformational change in an overlapping expression
platform, thus modulating gene expression, primarily through
transcription termination or translation initiation.1−3
RNA-based gene regulators, such as riboswitches, are an
attractive starting point for the development of new gene
expression tools for the synthetic biology and biotechnology
ﬁelds.4−8 RNA regulatory components have the advantage over
their protein counterparts in that they are inherently more
versatile, being relatively easy to design or manipulate in a
predictable manner and being transferable between organ-
isms.4−6 Natural riboswitches provide a diverse array of ready-
made components, with diﬀerent aptamer domains having been
identiﬁed for more than 20 speciﬁc metabolite ligands1,2 and
expression platforms that exhibit considerable mechanistic
diversity.1,2 The modularity of these regulatory components is
also demonstrated by the natural occurrence of tandem
riboswitches, which can function as two-input Boolean logic
gates or provide more binary switching responses.2 Despite these
advantages, most riboswitches respond to essential metabolites
that are present in cells at variable levels, and the exogenous
addition of metabolites at the concentrations required to
modulate riboswitch function could have adverse eﬀects,
perturbing global gene expression levels and cellular physiology.9
Engineered riboswitches that respond to synthetic non-natural
ligands, rather than metabolites, are highly desirable.4 The most
common strategy used to create such switches is to insert RNA
aptamers that have been generated by in vitro selection into the
5′-UTR of a target gene and to use a genetic selection or screen to
isolate functioning riboswitches.10−13 Recent studies have shown
that hybrid riboswitches can also be rationally designed, through
the fusion of synthetic aptamers with expression platforms
derived from natural riboswitches, to create functional chimeric
switches.14,15 In theory, it should be possible to generate a
riboswitch that responds to any ligand of choice using these
approaches. However, there is a limited availability of synthetic
aptamers that have been demonstrated to function as
components of riboswitches, with only theophylline and
tetracycline aptamers ﬁnding widespread use.16 This is because
the development of new aptamers in vitro can be laborious and,
critically, does not guarantee high speciﬁcity or functionality in
vivo.4,17
To address the need for new riboswitch-based gene expression
tools that respond to non-natural ligands, we previously reported
Received: April 1, 2015
Published: June 24, 2015
Article
pubs.acs.org/JACS
© 2015 American Chemical Society 9015 DOI: 10.1021/jacs.5b03405
J. Am. Chem. Soc. 2015, 137, 9015−9021
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
a strategy for re-engineering natural riboswitches to generate
orthogonal aptamer domains that are selective for artiﬁcial
ligands rather than the cognate natural metabolite.18−20 The
ligand binding site of the add A-riboswitch from Vibrio vulniﬁcus
was subjected to saturation mutagenesis; then, an exhaustive
chemical genetic selection strategy was used to identify
functional orthogonal riboswitch−ligand combinations.18
Through this approach, two novel mutant aptamer domains
were generated that respond to triazine-based ligands.18
Subsequent rounds of structure-guided screening identiﬁed
superior second-generation pyrimidopyrimidine ligands.20 In
principle, this strategy is applicable to any riboswitch. However,
the extensive selection and screening process adopted was
laborious, with more than 100 potential ligands being evaluated
against the panel of add riboswitch mutants.18,20 With hindsight,
the add A-aptamers could have been re-engineered through a
more rational approach. Indeed, a common feature of the
orthogonal aptamer−ligand pairings that we have identiﬁed is
that the direction of a few key hydrogen-bonding interactions
between the aptamer and ligand had been reversed, through
conservative uracil to cytosine mutations, with complementary
changes to the structure of the synthetic ligand. Consequently,
rational redesign of natural aptamer domains should be
achievable through mutations that reverse hydrogen-bond
directionality, disrupting interactions between the aptamer and
the natural ligand, while avoiding mutations that might adversely
aﬀect the global structure of the aptamer domain. In turn, a priori
knowledge of the structure of the re-engineered ligand-binding
pocket allows predictions to be made about the types of ligand
that are likely to bind, allowing more rapid and eﬀective
screening against a smaller targeted synthetic compound library.
In this article, we demonstrate how a rational approach can be
used to re-engineer the PreQ1 class I riboswitch from Bacillus
subtilis.21−23 PreQ1 class I riboswitches, commonly found in
Firmicutes and Proteobacteria,21,24 regulate genes required for
the biosynthesis of the hypermodiﬁed nucleotide queuosine,
present at the wobble position of GUN tRNAs.21,25 The minimal
PreQ1 aptamer domain is the smallest known riboswitch
aptamer, at just 34 nucleotides in length (Figure 1A), and is
selective for queuosine precursors 7-aminomethyl-7-deazagua-
nine (PreQ1) and 7-cyano-7-deazaguanine (PreQ0).
21 Ligand
binding stabilizes a H-type pseudoknot in the aptamer domain
(Figure 1B),22,23 which leads to the formation of a downstream
transcriptional terminator stem required to repress gene
expression (Figure S1).21 We introduced mutations at three
key sites in the ligand-binding pocket to disrupt hydrogen
bonding to the natural queuosine precursors, and these candidate
aptamers were evaluated in vivo against a small rationally
designed library of synthetic compounds. From this approach, a
functional mutant riboswitch−ligand pairing was identiﬁed that
was highly eﬀective in repressing gene expression in B. subtilis.
■ RESULTS AND DISCUSSION
Targeted Mutagenesis of the PreQ1 Riboswitch. The
PreQ1 class I riboswitch from B. subtilis was considered to be a
good candidate for re-engineering, as it is well-characterized and
analogues of the natural ligands are both synthetically accessible
and likely to be cell-permeable. From published structures of the
PreQ1 aptamer, it is apparent that Watson−Crick base pairing
between the conserved cytidine C17 residue and PreQ1 is
essential in ligand recognition.22,23 This canonical base pair
interaction, along with a trans sugar edge/Watson−Crick base
pairing with A30 and additional hydrogen bonding to G5 andU6,
allows for complete recognition of the PreQ1 ligand by the
riboswitch aptamer (Figure 1B,C). On the basis of these
structural insights, residues G5, U6, and C17, along with residue
C18 which Watson−Crick pairs with G5 in the P1 stem, were
subjected to site-directed mutagenesis to alter the binding
speciﬁcity of the aptamer toward new non-native ligands. A30
was not considered for mutagenesis, as it H-bonds to the C2-
amino group of the ligand. The C2-amino group was shown to be
essential for ligand binding by the PreQ1 riboswitch
21 and would
be required for H-bonding to either C17 or U17. To avoid
unnecessarily perturbing riboswitch folding, while keeping the
dimensions of the ligand-binding pocket constant, the trans-
version of pyrimidines to purines or vice versa was avoided,
resulting in a library of just seven mutants: the M1 (C17U), M2
(U6C), and M3 (G5A) single mutants; M4 (G5A, C18U) and
M5 (U6C, C17U) double mutants; M6 (G5A, C17U, C18U)
triple mutant; and M7 (G5A, U6C, C17U, C18U) quadruple
mutant.
It was anticipated that riboswitches possessing the C17U
mutation might recognize synthetic diamino-faced compounds
(Figure 2, 1−6). Similarly, U6Cwas envisaged to potentially alter
riboswitch speciﬁcity from the native deazapurine ligands to
furopyrimidines (3−6), whereas G5A might permit interactions
with compounds possessing diﬀerent C7 side chains (1 and 4−
6). Given that the G5A mutation was predicted to disrupt
formation of the P1 aptamer stem, the complementary C18Uwas
also included alongside G5A (see Figure S1 for further
information). The selected mutations were introduced into a
lacZ expression vector, in which the promoter and entire 5′-UTR
Figure 1. Secondary structure of the PreQ1-I aptamer and H-bond
ligand contacts. (A) Stems P1 (green) and P2 (blue) are connected
through three loop regions (L1−L3). (B) Stem P2 is formed through a
tertiary interaction, which is stabilized by ligand binding, resulting in a
H-type pseudoknot. (C) The PreQ1 ligand (blue) H-bonds with one
residue from each of the three loops, U6 (L1), C17 (L2), and A30 (L3).
This ligand-binding core is stacked between the two stems of the
aptamer, with the aminomethyl group of PreQ1 pointing out into the
major groove, where it interacts with G5 (P1) and the phosphate of G11
(P2). (See Figure S1 for more details.)
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of the queCDEF operon, encompassing the PreQ1 riboswitch
aptamer domain and expression platform, controlled expression
of the lacZ gene (Figures 2A and S2A).21 The constructs were
then integrated into the chromosome of B. subtilis to generate
reporter strains enabling riboswitch−ligand interactions to be
monitored in vivo using a modiﬁed Miller assay.26
In Vivo Functionality of PreQ1 Riboswitch Mutants.
Levels of β-galactosidase (LacZ) activity were determined
initially in the absence of ligand (Figure 2B). The strain
possessing the wild-type riboswitch produced very low basal
levels of LacZ activity, suggesting that cellular levels of PreQ1 and
PreQ0 were suﬃcient to bind the wild-type riboswitch and
repress LacZ expression; this demonstrates how the parent
riboswitch is of little utility as a regulatory tool in cells that
produce the natural ligands. In contrast, all of the mutant
riboswitch strains exhibited elevated levels of LacZ activity,
presumably because they no longer bind the native ligands or
because they have lost the ability to function as transcriptional
terminating elements. Subsequently, transformants were
screened for their ability to control LacZ expression in response
to the exogenous addition of PreQ0. The LacZ activity of all
mutant riboswitch transformants was unaﬀected by the addition
of exogenous PreQ0 (at 2.5 mM), demonstrating that these
mutants no longer respond to PreQ0 (Figure S3A). The Breaker
group previously reported structural modulation of a C17U
mutant of the PreQ1 riboswitch in the presence of 2,6-
diaminopurine (DAP).21 Therefore, we also tested DAP in our
assay, but no signiﬁcant repression of LacZ activity was observed
for any of our mutant PreQ1 riboswitches in the presence of 2.5
mM DAP (Figure S3B). This demonstrates that while DAP may
bind to the M1 (C17U) aptamer in vitro it is not capable of
controlling gene expression in vivo through theM1 riboswitch, so
it is not a suitable orthogonal riboswitch ligand.
The mutant strains fell into two distinct groups: those that
exhibited high levels of LacZ expression in the absence of ligand
(M1, M2, M5, and M7) and those that exhibited moderate levels
of LacZ expression (M3, M4, and M6). It was noted that the
moderate LacZ expressors all contained the G5A mutation,
which is situated underneath the ligand-binding pocket at the top
of the P1 stem. It is possible that this mutation leads to alternative
folding of the riboswitch, interfering with downstream tran-
scription (reducing LacZ expression). The compensatory C18U
mutation was designed to restore P1 stem integrity by allowing
base pairing to the G5Amutation; however, mutants M4 andM6
produced only intermediate levels of LacZ despite having both
mutations present. These data suggest that the G5A mutation is
unsuitable for the development of orthogonally selective PreQ1
riboswitches. In light of this, the single mutant M1 (C17U) and
double mutant M5 (U6C, C17U) were considered to be the best
candidates for the creation of orthogonally selective riboswitches
and were therefore prioritized for further study.
In Vivo Evaluation of Candidate Ligands. Six potential
ligand compounds 1−6 (Figure 2C) were designed and
synthesized, focusing on diamino-faced analogues of PreQ1 and
PreQ0, to target the C17U mutation present in both the M1 and
M5 riboswitches. In addition, four of these compounds were
synthesized with an oxygen at position 9 to accommodate the
U6C mutation in M5. This targeted compound library was
Figure 2. Screening PreQ1 riboswitch mutants for control of LacZ expression in B. subtilis. (A) Schematic of the chromosomally integrated LacZ
expression construct. The lacZ gene (blue box arrow) is transcribed from the B. subtilis queCDEF constitutive promoter (black line arrow). A wild-type
or mutant PreQ1 riboswitch (gray box) terminates transcription upon ligand binding. Riboswitch mutations tested in this study are tabulated. (B) β-
Galactosidase activity of wild-type andmutant riboswitch constructs assayed in the absence of exogenous ligand. (C) Structures of synthetic compounds
screened for activity withmutant riboswitch constructs. (D) β-Galactosidase activity of theM1 (C17U) riboswitch construct assayed in the presence of 1
mM of the compounds above. Data represent the mean of three repeats, with error bars indicating standard deviation.
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screened for the ability to repress LacZ activity controlled by
mutant riboswitchesM1 (Figure 2D) andM5 (Figure S4A). This
strategy identiﬁed a functional riboswitch−ligand pairing
between the M1 mutant and ligand 2, the diamino analogue of
PreQ0 (DPQ0). The M1 riboswitch exhibited selectivity,
mediating in vivo repression only in the presence of DPQ0 (2),
despite all library compounds having a diamino-face. Further-
more, when tested against other riboswitch mutants that contain
the C17U mutation (M1, M5, M6, and M7), DPQ0 was active
only against M1 (Figure S3C). The M1−DPQ0 pairing was
capable of dose-dependent control of lacZ expression, with an
IC50 value of 498 μM and ∼90% repression observed at DPQ0
concentrations of 2 mM or higher (Figure 3A). The proposed
binding model of M1 bound to DPQ0 (Figure 3B) shows how
the C17Umutation alters the base pairing complementarity from
the guanine-face of PreQ0 to the diamino-face of its analogue,
DPQ0. Since PreQ0 cannot repress the M1 riboswitch (Figure
S3A), this mutant riboswitch is orthogonal with respect to the
wild-type system in terms of in vivo functionality. Growth rate
studies (Figure S5) also reveal that DPQ0 is not toxic to B. subtilis
at concentrations required to modulate M1 riboswitch activity.
The U6Cmutation was rationalized to switch the speciﬁcity of
the riboswitch, from deazapurines, which possess an N9
hydrogen-bond donor, to synthetic furopyrimidines with an
O9 H-bond acceptor. Accordingly, several diamino-faced ligands
were synthesized with an oxygen at position 9 (3−6); however,
none of them were capable of repressing the M5 (U6C, C17U)
riboswitch under the conditions of our LacZ assay (Figure S4A).
The U6 residue also plays a role in PreQ1 riboswitch folding, as it
base pairs with the Hoogsteen edge of A29.22,23 This base pair
will be lost with the U6C mutation, which may disrupt aptamer
folding and ligand-binding kinetics. We therefore investigated
whether the M5 riboswitch could repress LacZ expression when
cells were grown at 16 °C, rather than at 37 °C (Figure S4B).
Under these conditions, ligand 3 was capable of modestly
repressing LacZ expression through the M5 riboswitch (28% at 2
mM), suggesting that lower temperatures stabilize the ligand-
bound pseudoknot and/or alter kinetics of transcription to allow
the riboswitch to function. Surprisingly, 3 was found to repress
LacZ expression under the control of the M1 riboswitch to an
even greater extent (59% at 2 mM), despite there being a
predicted lone pair clash between U6 and O9 of ligand 3. These
observations suggest that there may be some ﬂexibility in the
positioning of U6 to accommodate mismatches in H-bonding
potential, which, when combined with the structural disruption
resulting from mutation of this residue, indicate that U6 is not a
suitable target residue for creating robustly functioning
orthogonal riboswitch mutants.
In Vitro Characterization of DPQ0 Binding to the
Orthogonal M1 Riboswitch Aptamer. PreQ0 is converted
directly into PreQ1 by the NADPH-dependent enzyme QueF,
27
which reduces the nitrile group to an aminomethyl moiety. Since
DPQ0 is a diamino-faced analogue of PreQ0, the possibility that
QueF might reduce the nitrile group of DPQ0 in vivo was
investigated. The nitrile reductase QueF from B. subtilis was
overproduced in Escherichia coli by standard protocols. Although
recombinant QueF was shown to reduce PreQ0 in vitro (Figure
S6), it did not accept DPQ0 as an alternative substrate. This
suggests that DPQ0, and not its reduced aminomethyl derivative,
acts directly on the M1 riboswitch to control gene expression in
Bacillus.
To further conﬁrm that DPQ0 is the in vivo ligand for the M1
riboswitch, we used isothermal titration calorimetry (ITC) to
study the binding of DPQ0 and PreQ0 to in vitro transcribed M1
and wild-type aptamer domains. The native PreQ0 ligand was
found to bind to the wild-type 34 nt minimal aptamer domain
with an apparent equilibrium dissociation constant (KD) of 0.57
± 0.02 μM (Figure 4A,C). This value was larger than the 0.1 μM
KD reported from in-line probing analysis of PreQ0 binding to a
52 nt fragment of the B. subtilis PreQ1 riboswitch.
21 However,
this fragment included an additional stem loop structure (P0) at
the 5′-end of the minimal aptamer domain, which was reported
to increase aﬃnity of the aptamer for the natural ligand.21
Therefore, the apparent KD we report here for PreQ0 binding to
the minimal 34 nt aptamer is consistent with the modest decrease
in binding aﬃnity observed when the P0 stem is absent. The
synthetic ligandDPQ0 was found to bind themutantM1 aptamer
with an apparent KD of 14.6 ± 1.46 μM (Figure 4B,C), 26-fold
higher than that of the wild-type aptamer−PreQo pairing. This
reduction in binding aﬃnity might be attributed to perturbation
of the structure or folding of the aptamer−ligand complex as a
result of the mutation of a key residue (C17U) and its binding to
a synthetic ligand analogue. Importantly, in vitro orthogonality
was observed between the two aptamer−ligand pairings, as
PreQ0 was shown to have no aﬃnity for the mutant M1 aptamer
and, similarly, DPQ0 had no aﬃnity for the wild-type PreQ1
aptamer.
It was apparent from the ITC analysis that the predicted
stoichiometry of PreQ0 binding to the wild-type aptamer was too
low (Figure 4C). An n value of 0.27 suggests that only around
one-quarter of the aptamer sample was ligand-binding
Figure 3. Dose-dependent repression of gene expression using the
orthogonal M1 riboswitch. (A) B. subtilis cells with lacZ under
transcriptional control of the M1 riboswitch were assayed for β-
galactosidase activity with DPQ0 (6.25 μM to 4mM). Data represent the
mean of three repeats, with error bars indicating standard deviation. The
data were ﬁt with a four-parameter logistic function to derive an IC50 of
498 μM. (B) Proposed H-bonding model for DPQ0 (blue) binding to
the M1 riboswitch. The mutated C17U residue is shown in green. H-
bonds are depicted as red dashed lines.
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competent. We suspected that this was a consequence of a
previously reported PreQ1 aptamer dimerization artifact.
28,29 We
prepared aptamer samples incorporating the C12U mutation to
prevent dimerization without disrupting important interactions
in the aptamer−ligand complex.22,23 Although the C12U
mutation prevented aptamer dimerization, it reduced the aﬃnity
of the wild-type aptamer for PreQ0 (KD of 1.92 ± 0.08 μM) and
led to a lack of detectable binding between DPQ0 and the C12U
mutant of M1 (Figure S7). It should be noted that dimerization
of aptamers aﬀects only the n parameter during ITC analysis; all
other parameter calculations are dependent solely on an accurate
determination of the ligand concentration in the syringe.30
Therefore, apparentKD estimates presented here are nonetheless
reliable (Figure 4C).
Regulation of MreB Expression Demonstrates M1
Utility. MreB is an actin homologue that plays a crucial role in
maintaining the distinctive rod-shaped morphology of B. subtilis
and many other bacterial species and is a promising target for
antimicrobial drug screening.31 To demonstrate the potential
applications of our M1−DPQ0 riboswitch−ligand pairing in
controlling native gene expression, we created a strain of B.
subtilis in which the expression of MreB was placed under the
conditional control of the full-length M1 riboswitch (Figure 5A).
Wild-type B. subtilis, which can freely express MreB, adopts a
rod-shaped morphology (Figure 5B-I).32 AnmreB deletion strain
of B. subtilis (ΔmreB) exhibits compromised growth, with cells
round and swollen in shape (Figure 5B-II). A linear M1-mreB
construct was chromosomally integrated into ΔmreB cells at the
amyE locus to produce the repressible M1-mreB strain. In the
absence of ligand, MreB is expressed by the M1-mreB strain to
restore the rod-shaped morphology (Figure 5B-III), demonstrat-
ing that the integrated construct successfully complements the
ΔmreB phenotype. Following supplementation of the cell media
with DPQ0, M1 repressed expression of MreB in the M1-mreB
strain (Figure 5B-IV). In vivo orthogonality was demonstrated, as
the same concentration of PreQ0 had no morphological eﬀect on
M1-mreB cells (Figure 5B-VI). Similarly, the morphology of the
wild-type strain was unaﬀected by the addition of DPQ0 (Figure
5B-V), conﬁrming that the eﬀects of this ligand onM1-mreB cells
are mediated through the M1 riboswitch.
Measurement of B. subtilis cell dimensions (Figure S9)
revealed that while the addition DPQ0 had a signiﬁcant eﬀect
(P < 0.001) on the M1-mreB strain, reducing the mean length/
width ratio of cells from 3.64 to 1.74, it had little eﬀect on wild-
type cells (5.39 and 5.19 in the absence and presence of DPQ0,
respectively). These data indicate that DPQ0 aﬀects the
morphology of M1-mreB cells by repressing mreB expression
through its speciﬁc interaction with the M1 riboswitch.
Furthermore, western blotting revealed that MreB protein levels
were signiﬁcantly reduced in the M1-mreB strain following
incubation with DPQ0 (Figure S10). These studies show how the
orthogonal M1−DPQ0 riboswitch−ligand pairing can be used to
regulate the expression of native genes in B. subtilis, to
complement knockout phenotypes, for gene functional analysis,
and for other purposes.
Figure 4. ITC analysis of aptamer−ligand interactions. (A) Upper
panel: wild-type PreQ1 aptamer titrated with PreQ0. Lower panel:
binding isotherms for 18.7 μM wild-type (black circles) or mutant M1
(white diamonds) aptamers titrated with 150 μM PreQ0. (B) Upper
panel: mutant M1 aptamer titrated with DPQ0. Lower panel: binding
isotherms for 18.7 μMmutantM1 (black diamonds) or wild-type (white
circles) aptamers titrated with 225 μM DPQ0. Experiments were
conducted at 25 °C in 50 mM HEPES (pH 7.5) buﬀer containing 100
mMKCl and 20 mMMgCl2. (C) Curves were ﬁtted in Origin, using the
supplied software (MicroCal), to calculate the thermodynamic
parameters presented.
Figure 5. Controlling cell morphology using the orthogonal M1
riboswitch. (A) The MreB expression construct. The mreB gene (green
arrow) is transcribed from the B. subtilis queCDEF constitutive promoter
(black arrow). The M1 riboswitch (gray box) terminates transcription
upon binding DPQ0. (B) Conditional gene repression aﬀects B. subtilis
morphology. The MreB expression construct was chromosomally
integrated into an mreB knockout strain of B. subtilis (ΔmreB) to create
the repressible M1-mreB strain. Cells were imaged at 60×magniﬁcation:
(I) wild-type, (II) ΔmreB cells, (III) M1-mreB cells, (IV) M1-mreB cells
with 2 mM DPQ0, (V) wild-type cells with 2 mM DPQ0, and (VI) M1-
mreB cells with 2 mM PreQ0. For further images, see Figure S8,
Supporting Information.
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■ CONCLUSIONS
Natural riboswitch aptamer domains and expression platforms
represent a diverse toolbox of modular gene regulatory
components. However, if this resource is to be fully exploited
in the creation of new genetic circuits, there is a need to develop
riboswitch aptamers that are orthogonal to one another and that
respond to synthetic or non-native ligands. Previous eﬀorts to
develop synthetic aptamers or to re-engineer natural aptamers
have involved extensive in vitro selection4,17 or laborious
screening procedures.18,20 In this article, we demonstrate how
a more rational targeted approach can be used to streamline the
process of creating orthogonal riboswitch tools.
On the basis of previous biochemical and structural
studies,21−23 just seven variants of the PreQ1-I riboswitch and
six synthetic ligand candidates were designed and tested for their
ability to repress gene expression. A single mutant (C17U) M1,
which does not respond to the natural ligand PreQ0, was shown
to provide eﬀective dose-dependent repression of lacZ
expression in B. subtilis upon addition of a diamino analogue
DPQ0. ITC experiments revealed that M1 binds DPQ0, but has
no aﬃnity for PreQ0, and conversely that the wild-type aptamer
binds PreQ0, but not DPQ0. Interestingly, 2,6-diaminopurine
(DAP), which had previously been shown to bind to M1 in
vitro,21 was unable to modulate M1-lacZ expression in vivo. The
in vivo selectivity for DPQ0 over DAP may be due to diﬀerences
in the rates of ligand−riboswitch association.21 Similar kinetic
selectivity is suggested to account for how the PreQ1 riboswitch
discriminates between PreQ1 and guanine in vivo, despite binding
both ligands in vitro.21 In addition, M1 and a double mutant
(U6C, C17U), M5, designed to recognize furopyrimidine
analogues, aﬀorded repression of lacZ expression with
furopyrimidine 3, but they did so only when cells were grown
at lower temperature (16 °C). The riboswitch−furopyrimidine
complexes may be unstable at higher temperatures, or,
alternatively, the kinetics of riboswitch ligand binding and
transcription may be less favorable.
To demonstrate the general applicability of the orthogonal
M1−DPQ0 riboswitch, we created conditional mutants of the
bacterial actin homologue MreB in B. subtilis, enabling cell
morphology to be controlled through the exogenous supply of
DPQ0. MreB is essential for the normal growth of rod-shaped
bacteria and has been identiﬁed as a potential antibiotic target.31
The dose-dependent control of mreB expression levels could
provide, therefore, a useful tool in creating sensitive strains for
antibiotic screening. Establishing tunable conditional mutants of
essential genes in pathogenic strains is important in antimicrobial
target validation and whole cell screening;33−35 by lowering the
levels of essential gene products in the cell, it is possible to
develop more sensitive screens for compounds that selectively
inhibit their function. Many important pathogenic and antibiotic-
resistant bacteria contain native PreQ1 riboswitches, including
Firmicutes (e.g., Staphylococcus, Clostridium, Listeria, Enter-
ococcus) and Proteobacteria (e.g., Campylobacter, Salmonella,
Neisseria).24 M1 variants of the native PreQ1 riboswitches might
be deployed, therefore, as host-optimized expression tools for
antibiotic screening and target validation purposes in these
pathogenic strains. Such tools would be timely given the
problems of antimicrobial resistance and the lack of alternative
tunable expression systems for interrogating many microbial
pathogens.
■ MATERIALS AND METHODS
Ligand Synthesis. Pyrrolo[2,3-d]pyrimidines (PreQ0, 1 and 2) and
furo[2,3-d]pyrimidines (3-6) were prepared in one or two synthetic
steps from the inexpensive precursors, 2,4,6-triaminopyrimidine or 2,4-
diamino-6-hydroxypyr-imidine (Sigma-Aldrich), following established
procedures (see the Supporting Information for full details).
Construction of the Riboswitch-Controlled LacZ Expression
Constructs. The pDG1661 vector36 containing the native promoter
and the entire PreQ1 riboswitch, ampliﬁed from the upstream region of
B. subtilis queCDEF operon (Figure S2A), was kindly supplied by the
Breaker lab.21 To generate riboswitch mutants, two ﬂanking master
primers (MC4 and MC5) and two internal mutagenic primers (MC6 to
MC19) were designed to amplify 5′ and 3′ fragments of the PreQ1
riboswitch (Table S1). Overlapping PCR was then employed to join
both fragments together, generating the complete mutant PreQ1
riboswitch sequences, which were cloned into the EcoRI and BamHI
sites of pDG1661, upstream of the lacZ reporter gene. The resulting
plasmids were veriﬁed by sequencing and transformed into B. subtilis
1A40, where they integrated into the amyE locus of the chromosome by
homologous recombination.21
β-Galactosidase (LacZ Expression) Assays. A high-throughput
microplate method for quantifying β-galactosidase activity in B. subtilis
was modiﬁed from that described in Lynch et al.26 Overnight cultures
were diluted 50-fold into 190 μL of nutrient broth, containing 5 μg/mL
chloramphenicol and either 10 μL of ligand in DMSO or with DMSO
alone, and were then left to grow in a 96-well plate at 37 °C. Amicroplate
reader (Anthos Zenyth 3100) was used to monitor OD595 until it
reached the 0.085−0.14 range (equivalent to an OD595 of 0.3−0.5 in a 1
cm path length cuvette); cells were then lysed by the addition of 20 μL
PopCulture reagent (Novagen), containing 40 U/mL lysozyme. Lysed
cultures were diluted 10-fold into 150 μL of Z buﬀer (60 mMNa2HPO4,
40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 mM β-
mercaptoethanol, pH 7.0). The β-galactosidase reaction was started
by adding 30 μL of O-nitrophenyl-β-D-galactoside (4 mg/mL in Z
buﬀer), incubated at 30 °C until a yellow color developed, and then
quenched by adding 75 μL of 1 MNa2CO3. The length of time between
substrate addition and quenching and the OD405 were recorded. The
Miller units were calculated using the following formula: Miller units =
1000× {OD405/(OD595× time× [volume of cell lysate/total volume])}
Preparation of RNA Aptamers and Isothermal Titration
Calorimetry. Riboswitch aptamers were prepared by in vitro tran-
scription following a protocol modiﬁed from Gurevitch.37 Brieﬂy,
dsDNA templates (comprising the aptamer sequence downstream of
the T7 RNA polymerase promoter) were created by annealing
complementary primers purchased from Sigma-Aldrich (Table S1).
Transcription reactions were performed by incubating T7 RNA
polymerase with dsDNA templates and 6 mM each of ATP, UTP,
GTP, CTP, in 30 mM Tris buﬀer (pH 8.0), 28 mM MgCl2, 20 mM
DTT, 3.4 mM spermidine, and 0.01% Triton X-100, for 4 h at 37 °C.
Transcription reactions were resolved by 12% PAGE under denaturing
conditions (8 M urea), with bands excised and RNA recovered by the
crush-and-soak method. Aptamers were then dialyzed overnight at 4 °C
into ITC buﬀer: 50 mMHEPES (pH 7.5), 100 mMKCl, 20 mMMgCl2.
Ligand solutions were prepared in the same buﬀer following dialysis.
Samples were degassed, and ITC experiments were performed at 25 °C
using a VP-ITC microcalorimeter (Microcal Inc.). Experiments were
conducted with the RNA aptamer sample in the cell, titrated with one 2
μL injection and then twenty-four 12 μL injections of ligand solution.
Construction of the M1 Riboswitch-Controlled mreB Ex-
pression Construct. The mreB gene was ampliﬁed from B. subtilis 168
by primers MC20 and MC21 (Table S1) and cloned into the EcoRI and
BamHI sites of pDG1662. A sequence composed of the amyE-front
fragment and mreB gene was ampliﬁed using primers MC22, MC23,
MC24, and MC25. Separately, another sequence composed of the M1-
riboswitch mutant, the cat (chloramphenicol resistance) gene, and the
amyE-back fragment was ampliﬁed from the corresponding LacZ
expression construct in pDG1661 (see above) using primers MC26,
MC27, MC28, and MC29. The two sequences were spliced together
through an identical 50 bp linker region by overlapping PCR to generate
a linear construct with ﬂanking amyE-front and amyE-back sequences
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for homologous recombination (Figure S2B). This linear DNA
construct was transformed into B. subtilis 3725 cells and integrated
into the amyE locus. Cell morphology (MreB expression) assays were




Further experimental information; details of ligand synthesis and
characterization. Figure S1: Mechanism and mutagenesis of the
PreQ1 class I riboswitch from the queCDEF operon of B. subtilis.
Figure S2: Construction of the LacZ and MreB expression
constructs. Figure S3: Screening PreQ1 riboswitch mutants for
control of LacZ expression. Figure S4: Screening for compounds
which repress the PreQ1 riboswitch mutant M5. Figure S5:
Eﬀects of DPQ0 on the growth of B. subtilis. Figure S6: QueF
nitrile reductase assay. Figure S7: Analysis of PreQ1 aptamers
mutated to prevent dimerization. Figure S8: Additional
microscopy images of B. subtilis cells used in the MreB study.
Figure S9: Cellular dimensions measured for various B. subtilis
strains in the presence or absence of the indicated compounds.
Figure S10: Analysis of MreB protein expression. Table S1:
Primers used in this study. The Supporting Information is
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